Aquestive Therapeutics (NASDAQ:AQST) PT Raised to $10.00 at HC Wainwright

Aquestive Therapeutics (NASDAQ:AQST) had its target price raised by equities researchers at HC Wainwright from $9.00 to $10.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 110.08% from the stock’s previous close.

Separately, JMP Securities reissued a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research report on Monday, August 12th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $8.67.

Aquestive Therapeutics Stock Down 4.4 %

Shares of Aquestive Therapeutics stock opened at $4.76 on Monday. The firm has a market cap of $433.35 million, a P/E ratio of -11.33 and a beta of 2.84. The business has a 50-day moving average price of $4.26 and a 200 day moving average price of $3.68. Aquestive Therapeutics has a fifty-two week low of $1.25 and a fifty-two week high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.08. The firm had revenue of $20.10 million during the quarter, compared to analyst estimates of $12.62 million. During the same quarter last year, the company earned ($0.10) earnings per share. As a group, equities research analysts anticipate that Aquestive Therapeutics will post -0.47 earnings per share for the current year.

Hedge Funds Weigh In On Aquestive Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Sanctuary Advisors LLC acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter valued at $165,000. Blue Owl Capital Holdings LP grew its holdings in shares of Aquestive Therapeutics by 30.3% in the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock valued at $2,964,000 after buying an additional 265,000 shares during the period. The Manufacturers Life Insurance Company acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter valued at $76,000. Deerfield Management Company L.P. Series C acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter valued at $380,000. Finally, Marshall Wace LLP acquired a new position in Aquestive Therapeutics in the 2nd quarter worth $200,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.